Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals reported governance updates and voting results from its 2026 annual stockholder meeting. The board appointed biopharmaceutical executive Ludwig Hantson, Ph.D., effective June 4, 2026. He brings more than 30 years of leadership experience at companies including Alexion, Baxter Bioscience/Baxalta, Novartis and Johnson & Johnson.
Stockholders elected directors Spencer R. Berthelsen and Joan E. Herman and approved, on an advisory basis, the compensation of named executive officers. They approved increasing the 2011 Equity Incentive Plan share authorization by 9,500,000 shares to 52,000,000 shares and expanding the Employee Stock Purchase Plan by 750,000 shares while removing its termination date. Stockholders also ratified Ernst & Young LLP as independent auditors for the 2026 fiscal year.
IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen reported an option exercise paired with a share sale. On June 1, 2026, he exercised a non-qualified stock option for 8,000 shares of common stock at $24.42 per share and then sold 8,000 shares in an open-market transaction at $75.67 per share. After these transactions, he directly held 156,013 shares of common stock. The filing also shows 70 shares held indirectly by his daughter, for which he disclaims beneficial ownership. The sale was executed under a Rule 10b5-1 Trading Plan adopted on September 12, 2025, indicating it was pre-arranged.
Ionis Pharmaceuticals reported that its partner GSK released positive pivotal Phase 3 data for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B. Across the B-Well 1 and B-Well 2 trials, six months of treatment produced a 19% functional cure rate (233 of 1,220) in adults with baseline hepatitis B surface antigen ≤3000 IU/mL, compared with 0% in the placebo group, meeting the primary endpoints.
In patients with baseline HBsAg ≤1000 IU/mL, a key secondary endpoint showed a 26% functional cure rate (200 of 768 vs. 0 of 393 on placebo). An exploratory analysis found 49% of bepirovirsen recipients reached qHBsAg ≤100 IU/mL one year after treatment, and 23% overall (31% in the ≤1000 IU/mL subgroup) achieved sustained DNA <LLOQ at week 72. Bepirovirsen is under FDA priority review with Breakthrough and Fast Track designations and is also under review in Europe, Japan and China. Ionis is eligible for additional regulatory and sales milestone payments and tiered royalties of 10–12% on net sales.
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported an exercise-and-sell transaction in company stock. On May 13–14, Monia exercised options to acquire a total of 4,536 shares of common stock at an exercise price of $32.60 per share, then sold the same number of shares in open-market trades at weighted average prices of about $78.01 and $78.68. The sales were carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 8, 2025. Following these transactions, Monia directly holds 242,662 shares of Ionis common stock, indicating that only a small portion of the position was sold.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,159,027 shares of Ionis Pharmaceuticals common stock, representing 3.7% of the class. The filing states sole voting power over 6,140,820 shares and sole dispositive power over 6,159,027 shares.
The filing is an amendment (Schedule 13G/A, Amendment No. 5) signed on 05/15/2026 and includes a statement that the filer denies beneficial ownership for the securities referenced. The CUSIP is 462222100 and the issuer is Ionis Pharmaceuticals, Inc.
Capital World Investors filed an amended Schedule 13G/A reporting beneficial ownership of 21,186,369 shares of Ionis Pharmaceuticals common stock, representing 12.8% of the 165,192,011 shares outstanding as of 03/31/2026. The filing states CWI has sole voting and dispositive power over these shares. The amendment is signed by a CRMC officer on 05/13/2026.
IONS — Form 144 notice of proposed sale by an affiliate. The filing lists proposed sales of Common Stock by Brett Monia, including 126,670 shares on 03/09/2026 for $9,525,059.00 and 34,103 shares on 03/10/2026 for $2,589,144.00. The filing also lists two historic stock option grants of 50,000 shares each (01/04/2021 and 01/03/2022) described as Equity Compensation.
Ionis Pharmaceuticals director Joseph Loscalzo reported paired option exercises and stock sales on May 4, 2026. He sold a total of 77,289 shares of Common Stock in open-market transactions at weighted average prices of $75.58 and $74.90, under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 18, 2025. To fund these sales, he exercised non-qualified stock options covering 77,289 shares at exercise prices between $38.06 and $64.80. Following the transactions, he continued to hold more than 36,000 shares of Ionis stock directly.
Ionis Pharmaceuticals director Joseph Klein III exercised a non-qualified stock option for 10,111 shares of common stock at an exercise price of $47.11 per share and, on the same date, sold 10,111 shares in open-market transactions under a pre-arranged Rule 10b5-1 Trading Plan. The sales consisted of 8,680 shares at a weighted-average price of $73.3530 and 1,431 shares at a weighted-average price of $74.4474. Following these transactions, Klein held 11,014 shares of Ionis common stock directly. An additional 100 shares are held indirectly by his son, and Klein disclaims beneficial ownership of those shares.